This new initiative brings together provider groups, purchasers and end users committed to evidence-based, cost-effective, equitable digital health solutions.
In a time where the demand for digital health technologies is needed, the Digital Health Collaborative, a new organization dedicated to advancing the evidence and adoption of digital health solutions, has gained support from 14 leading healthcare and consumer organizations.
Despite advancements in this space, purchasers are challenged with determining the best solutions for their digital health needs.
This new initiative brings together provider groups, purchasers and end users committed to evidence-based, cost-effective, equitable digital health solutions.
The Peterson Health Technology Institute (PHTI), an initiative of the Peterson Center on Healthcare, is a supporter of the Collaborative.
PHTI assesses digital health solutions to determine their clinical effectiveness and financial impact for purchasers like payers, providers, and employers on behalf of patients.
Meg Baron, managing director of engagement and outreach at PHTI shared with Managed Healthcare Executive, "Collaborative members will jointly work together on research, programs, and knowledge sharing to help raise purchaser confidence and adoption of digital health solutions. Initial activities will include a national survey of digital health purchasers, grantmaking through a Research and Impact Fund, and regular convenings, including at an annual Summit."
Collaborative members include:
Through support from PHTI, the Collaborative will offer the Research and Impact Fund for aligned research and programs.
The first grant was awarded to DiMe for its Integrated Evidence Plans for Digital Health Products project to help developers align digital health products with purchaser evidence requirements.
“With a growing market of digital health solutions available to providers and consumers, the Digital Health Collaborative will play an important role in helping to bring together the perspectives and voices across the health system to meaningfully share insights on new and emerging technology,” Danielle Lloyd, senior vice president of Private Market Innovations and Quality at AHIP, said. “We hope the Collaborative’s research, analysis and data initiatives can help fill important gaps in assessing clinical value and health outcomes for stakeholders across the health system.”
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Omega-3s For Dry Eye Disease? Not the Answer According to This Study
May 17th 2024Some research has suggested that omega-3 fatty acid supplements could help treat dry eye disease. But Korean investigators reported results from a randomized clinical trial this week in JAMA Ophthalmology tthat showed no benefit.
Read More